International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

NCT07476729 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

750

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Acute Lymphoblastic Leukaemia

Interventions

DRUG: Inotuzumab ozogamicin (INO)
DRUG: Blinatumomab

Sponsor

Charite University, Berlin, Germany